ROCKET PHARMACEUTICALS, INC. (RCKT): M&A transaction — Rocket Pharmaceuticals completes acquisition of Renovacor; gains BAG3-DCM gene therapy REN-001

ROCKET PHARMACEUTICALS, INC.

Renovacor shareholders received 0.1763 shares of Rocket common stock per Renovacor share.
Acquisition extends Rocket's AAV-based cardiac gene therapy leadership with REN-001 targeting BAG3-associated dilated cardiomyopathy.
Rocket gains Renovacor's IP, scientific collaborators, and BAG3-DCM expertise.
Renovacor shares ceased trading on NYSE; Rocket continues on Nasdaq as RCKT.
Stockholders approved the share issuance proposal at Nov 30 special meeting with ~99.9% votes for.

item 2.01 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ROCKET PHARMACEUTICALS, INC. completed an acquisition involving Renovacor, Inc. (closed 2022-12-01).

Action: acquisition
Counterparty: Renovacor, Inc.
Closing: 2022-12-01

Exact text from the filing

On December 1, 2022, pursuant to the terms of the Merger Agreement, (i) Merger Sub I merged with and into the Company (the “First Merger”) and (ii) the Company, as the surviving company of the First Merger, merged with and into Merger Sub II (the “Second Merger” and together with the First Merger, the “Mergers”), with Merger Sub II surviving the Mergers.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

ROCKET PHARMACEUTICALS, INC. shareholders approved To approve the issuance of Parent Shares to security holders of Renovacor, as contemplated by the Merger Agreement pursuant to Nasdaq Rule 5635(a)(2) at the 2022-11-30 meeting.

Proposal: merger approval
Outcome: passed
Meeting: 2022-11-30

Exact text from the filing

Rocket Share Issuance Proposal . To vote to approve the issuance of Parent Shares to security holders of Renovacor, as contemplated by the Merger Agreement pursuant to Nasdaq Rule 5635(a)(2) (the “Rocket Share Issuance Proposal”). Votes For Votes Against Abstentions 58,919,928 45,017 51,950

View on SEC.gov

Browse all m&a transactions →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-22-044043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.